SCHEMBL2071793

SCHEMBL2071793

N#Cc1ccc(C2=CC3CCC(C2)N3C(=O)N2CCCc3ccccc32)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.45
TSHR P16473 3/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
POLB P06746 2/20 0.42
NOTUM Q6P988 1/20 0.40
UCHL1 P09936 1/20 0.40
USP30 Q70CQ3 1/20 0.40
FPR1 P21462 2/20 0.39
FPR2 P25090 2/20 0.39
AVPR2 P30518 1/20 0.38
OXTR P30559 1/20 0.38
AVPR1A P37288 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2071794 1.00 HSD11B1 (0.45) HSD11B1TSHRMEN1USP2ALDH1A1
SCHEMBL3942371 0.93 HSD11B1 (0.40) HSD11B1TSHRMEN1USP2ALDH1A1
SCHEMBL3942367 0.93 HSD11B1 (0.40) HSD11B1TSHRMEN1USP2ALDH1A1
SCHEMBL2070475 0.91 USP30 (0.43) HSD11B1TSHRMEN1USP2ALDH1A1
SCHEMBL2070472 0.91 USP30 (0.43) HSD11B1TSHRMEN1USP2ALDH1A1
SCHEMBL2071649 0.87 AVPR2 (0.47) HSD11B1TSHRSMN1; SMN2POLBNOTUM
SCHEMBL2073320 0.87 PDE4B (0.48) HSD11B1TSHRMEN1USP2ALDH1A1
SCHEMBL2073318 0.87 PDE4B (0.48) HSD11B1TSHRMEN1USP2ALDH1A1
SCHEMBL2071679 0.87 POLB (0.52) HSD11B1TSHRMEN1ALDH1A1KMT2A
SCHEMBL2073220 0.87 PDE4B (0.48) HSD11B1TSHRMEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897773-B2 Urea derivatives of tropane, their preparation and their therapeutic application SANOFI-AVENTIS (FR) 2011-03-01 US disclosed
US-20100324084-A1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2010-12-23 US disclosed
EP-2046791-B1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-03-24 EP disclosed
US-20090170894-A1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170894-A1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HSD11B1, ADRA1D, HSD17B1 HSD11B1 1/4885TSHR 846/4885MEN1 3804/4885
US-20100324084-A1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HSD11B1, ADRA1D, HSD17B1 HSD11B1 1/4885TSHR 846/4885MEN1 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.